Protection of Prior SARS-CoV-2 Infection Against Different Variants, Including Omicron Descendants, in a Country with High Viral Transmission
Article Sidebar
Main Article Content
Abstract
Background: Prior infection with SARS-CoV-2 has been reported to confer protection against reinfections. Because Peru has been affected by several variants of this virus, it is an ideal location to better explore this phenomenon. In this study, we aim to evaluate protection of prior SARS-CoV-2 infection against reinfection by variants during the COVID-19 pandemic in Peru.
Methods: A nested case-control study was carried out, using national data from Peru between 2021 and 2023. Five study periods were defined, delimited by the predominance of the main SARS-CoV-2 variants circulating during the pandemic. Cases were paired with controls in a 1 to 4 rate by sex, age, region, being a health worker, and the week of infection. Protection was calculated using conditional logistic regression to estimate odds ratios (OR) with 95% confidence intervals (95% CI) expressed as (1-OR) x100.
Results: Protection from prior infection against SARS-CoV-2 reinfection was 86.3% (95% CI, 81.8 to 89.7) for Lambda, 73.0% (95% CI, 62.9 to 80.3) for Gamma, 84.7% (95% CI, 82.1 to 86.9) for Delta, 34.9% (95% CI, 25.5 to 43.1) for Omicron BA.1, 67.0% (95% CI, 58.7 to 73.6) for Omicron BA.2.12.1, 49.1% (95% CI, 40.5 to 56.5) for Omicron BA.4, 44.8% (95% CI, 39.9 to 49.3) for Omicron BA.5, 29.4% (95% CI, 18.2 to 39.1) for Omicron BQ, and 8.6% (95% CI, -0.5 to 16.9) for Omicron XBB.
Conclusions: Prior infection provides a significant protection against SARS-CoV-2 reinfection episodes, although this varies widely among the different Omicron sublineages.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. Amin R, Sohrabi MR, Zali AR, Hannani K. Five consecutive epidemiological waves of COVID-19: a population-based cross-sectional study on characteristics, policies, and health outcome. BMC Infect Dis. 2022;22(1):906. doi: http://dx.doi.org/10.1186/s12879-022-07909-y">10.1186/s12879-022-07909-y. PubMed PMID: 36471283; PMCID: PMC9721063.
2. Kaye AD, Okeagu CN, Pham AD, Silva RA, Hurley JJ, Arron BL, Sarfraz N, Lee HN, Ghali GE, Gamble JW, Liu H, Urman RD, Cornett EM. Economic impact of COVID-19 pandemic on healthcare facilities and systems: International perspectives. Best Pract Res Clin Anaesthesiol. 2021;35(3):293-306. doi: http://dx.doi.org/10.1016/j.bpa.2020.11.009">10.1016/j.bpa.2020.11.009. PubMed PMID: 34511220; PMCID: PMC7670225.
3. Akande OW, Akande TM. COVID-19 pandemic: A global health burden. Niger Postgrad Med J. 2020;27(3):147-55. doi: http://dx.doi.org/10.4103/npmj.npmj_157_20">10.4103/npmj.npmj_157_20. PubMed PMID: 32687112.
4. Dutta A. COVID-19 waves: variant dynamics and control. Sci Rep. 2022;12(1):9332. doi: http://dx.doi.org/10.1038/s41598-022-13371-2">10.1038/s41598-022-13371-2. PubMed PMID: 35661125; PMCID: PMC9166180.
5. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Consortium C-GU, Peacock SJ, Robertson DL. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409-24. doi: http://dx.doi.org/10.1038/s41579-021-00573-0">10.1038/s41579-021-00573-0. PubMed PMID: 34075212; PMCID: PMC8167834.
6. Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, Coyle P, Yassine HM, Al-Khatib HA, Benslimane FM, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Tang P, Abu-Raddad LJ. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N Engl J Med. 2022;386(13):1288-90. doi: http://dx.doi.org/10.1056/NEJMc2200133">10.1056/NEJMc2200133. PubMed PMID: 35139269; PMCID: PMC8849180.
7. Altarawneh HN, Chemaitelly H, Ayoub HH, Hasan MR, Coyle P, Yassine HM, Al-Khatib HA, Smatti MK, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Tang P, Abu-Raddad LJ. Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. N Engl J Med. 2022;387(17):1620-2. doi: http://dx.doi.org/10.1056/NEJMc2209306">10.1056/NEJMc2209306. PubMed PMID: 36198139; PMCID: PMC9559315.
8. Prillaman M. Prior Omicron infection protects against BA.4 and BA.5 variants. Nature. 2022. doi: http://dx.doi.org/10.1038/d41586-022-01950-2">10.1038/d41586-022-01950-2. PubMed PMID: 35864323.
9. Pampa-Espinoza L, Padilla-Rojas C, Silva-Valencia J, Jimenez-Vasquez V, Silva I, Mestanza O, Lope Pari P, Caceres O, Bailon-Calderon H, Barcena-Flores L, Galarza M, Garcia Mendoza M, Gavilan R, Rojas Serrano N, Palomino Rodriguez M, Huaringa M, Rios Monteza P, Ordonez L, Fernandez-Navarro M, Vargas-Herrera N, Solari L. Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 Reinfections After a Second Wave With Predominance of Lambda in Lima and Callao, Peru. Open Forum Infect Dis. 2022;9(6):ofac134. doi: http://dx.doi.org/10.1093/ofid/ofac134">10.1093/ofid/ofac134. PubMed PMID: 35615298; PMCID: PMC9125301.
10. Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L, Ho DD. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186(2):279-86 e8. doi: http://dx.doi.org/10.1016/j.cell.2022.12.018">10.1016/j.cell.2022.12.018. PubMed PMID: 36580913; PMCID: PMC9747694.
11. Pampa-Espinoza L, Silva-Valencia J, Fernandez-Navarro M, Padilla-Rojas C, Solari L. Reinfections Are More Frequent Than Currently Considered in Countries With High Incidence of Coronavirus Disease 2019 (COVID-19) Cases Due to Stringent Definitions. Clin Infect Dis. 2022;74(8):1505-6. doi: http://dx.doi.org/10.1093/cid/ciab783">10.1093/cid/ciab783. PubMed PMID: 34508348; PMCID: PMC8499902.
12. Hoffmann M, Kruger N, Schulz S, Cossmann A, Rocha C, Kempf A, Nehlmeier I, Graichen L, Moldenhauer AS, Winkler MS, Lier M, Dopfer-Jablonka A, Jack HM, Behrens GMN, Pohlmann S. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447-56 e11. doi: http://dx.doi.org/10.1016/j.cell.2021.12.032">10.1016/j.cell.2021.12.032. PubMed PMID: 35026151; PMCID: PMC8702401.
13. Strategic Advisory Group of Experts on Immunization B. Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine. World Heath Organization, 2021 2021/05/07/. Report No.
14. Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, Wang J, Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X, Du S, Zhang Z, Hao X, Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657-63. doi: http://dx.doi.org/10.1038/s41586-021-04385-3">10.1038/s41586-021-04385-3. PubMed PMID: 35016194; PMCID: PMC8866119.
15. Carreno JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, Sominsky LA, Clark JJ, Adelsberg DC, Bielak DA, Gonzalez-Reiche AS, Dambrauskas N, Vigdorovich V, Group P-PS, Srivastava K, Sather DN, Sordillo EM, Bajic G, van Bakel H, Simon V, Krammer F. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. 2022;602(7898):682-8. doi: http://dx.doi.org/10.1038/s41586-022-04399-5">10.1038/s41586-022-04399-5. PubMed PMID: 35016197.
16. Carreno JM, Alshammary H, Singh G, Raskin A, Amanat F, Amoako A, Gonzalez-Reiche AS, van de Guchte A, Study Group P, Srivastava K, Sordillo EM, Sather DN, van Bakel H, Krammer F, Simon V. Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients. EBioMedicine. 2021;73:103626. doi: http://dx.doi.org/10.1016/j.ebiom.2021.103626">10.1016/j.ebiom.2021.103626. PubMed PMID: 34688034; PMCID: PMC8527879.
17. Oxford Analytica. Rapid Omicron spread may dampen recovery in Peru. Emerald Expert Briefings [Internet]. 2022 2022/01/01/. doi: http://dx.doi.org/10.1108/oxan-db266708">10.1108/oxan-db266708.Available from: https://www.emerald.com/insight/content/doi/10.1108/OXAN-DB266708/full/html">https://www.emerald.com/insight/content/doi/10.1108/OXAN-DB266708/full/html
18. Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X, Yu Y, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z, Wang Y, Wang X, Xiao J, Xie XS. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608(7923):593-602. doi: http://dx.doi.org/10.1038/s41586-022-04980-y">10.1038/s41586-022-04980-y. PubMed PMID: 35714668; PMCID: PMC9385493.
19. Vikse EL, Fossum E, Erdal MS, Hungnes O, Bragstad K. Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022. Influenza Other Respir Viruses. 2023;17(6):e13144. doi: http://dx.doi.org/10.1111/irv.13144">10.1111/irv.13144. PubMed PMID: 37273461; PMCID: PMC10236499.
20. Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, Xie X, Shi PY. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2023;29(2):344-7. doi: http://dx.doi.org/10.1038/s41591-022-02162-x">10.1038/s41591-022-02162-x. PubMed PMID: 36473500.
21. Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K, Cutler M, Cooper D, Yang Q, Cai H, Muik A, Zhang Y, Lee DY, Sahin U, Anderson AS, Gruber WC, Xie X, Swanson KA, Shi PY. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine. N Engl J Med. 2023;388(9):854-7. doi: http://dx.doi.org/10.1056/NEJMc2214916">10.1056/NEJMc2214916. PubMed PMID: 36734885; PMCID: PMC9891359.
22. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, Dushoff J, Mlisana K, Moultrie H. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022;376(6593):eabn4947. doi: http://dx.doi.org/10.1126/science.abn4947">10.1126/science.abn4947. PubMed PMID: 35289632; PMCID: PMC8995029.
23. Peeling RW, Olliaro PL, Boeras DI, Fongwen N. Scaling up COVID-19 rapid antigen tests: promises and challenges. Lancet Infect Dis. 2021;21(9):e290-e5. doi: http://dx.doi.org/10.1016/S1473-3099(21)00048-7">10.1016/S1473-3099(21)00048-7. PubMed PMID: 33636148; PMCID: PMC7906660.
24. Centro Nacional de Epidemiolgía Prevención y Control de E. Fortalecimiento de la vigilancia epidemiológica comunitaria para la identificación oportuna y seguimiento de casos de COVID -19. ALERTA EPIDEMIOLOGICA. Peru: CDC-Peru, 2020 2020/12/11/. Report No.: AE_029-2020.
25. Centro Nacional de Epidemiolgía Prevención y Control de E. Alerta epidemiológica para la aplicación de pruebas diagnósticas en casos de COVID-19 en el Perú. ALERTA EPIDEMIOLOGICA. Peru: Centro Nacional de Epidemiolgía Prevención y Control de Enfermedades, 2020 2020/09/30/. Report No.: AE-021-2020.
26. Hanrath AT, Payne BAI, Duncan CJA. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. J Infect. 2021;82(4):e29-e30. doi: http://dx.doi.org/10.1016/j.jinf.2020.12.023">10.1016/j.jinf.2020.12.023. PubMed PMID: 33373652; PMCID: PMC7832116.